Genmab — Oktober 2020

[E_L]

and Society for Immunotherapy of Cancer
@sitcancer
suddenly started following me on twitter; they are on to me !

[Bulder]

[Solsen]

Det var spændende data på GEN1046, men vi må vente med at se hvor gode de egentlig er. Mange ots kun behandlet e

[Solsen]

Mange patienter kun behandlet kort tid og flere med meget små doser.

[Solsen]

Ja Ocrevus er vild. Også spændende hvad Novartis kan gøre ved Roche.

[E_L]

just checked we have to wait till oct27 for Novartis Q3 to get the first glimpse

[E_L]

New trial: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04586426

[GeorgeBest]

Any opinion about the liver tox in GEN1046?

[E_L]

"sorry can't tell you; it is under embargo"

[E_L]

There was transaminise elevation , 24.6% all grades, 9.8% grade 3-4

[E_L]

treatment related grade-3 transaminase elevatoins decreased upon corticosteroid administration, no treatment related bilirubin increases or grade-4 transaminase elevatoins occured

[E_L]

so in summary they concluded manageable safety profile

[GeorgeBest]

Thank you, there were some doubts from Nordea, but very impressive on efficiacy on those heavily pretreated patients they apparently concluded

[E_L]

did Nordea base their doubts on that abstract?

[GeorgeBest]

Yes

[GeorgeBest]

I have not seen the note myself, but 6 patients had dose limiting tox incl elevated liver enzymes they write

[GeorgeBest]

Liver tox have in the past been a problem and hindernis for 4-1BB drugs, and therefore this has to be monitored closely they conclude

[E_L]

yes, offcourse

[E_L]

6 out of 61, treatment with corticosteroid seems to help, maximum tolerated dose was not reached

[E_L]

exactly because liver tox was an issue before, I was not disappointed with this. Surely we'll hear a bit more about this in november